Hyris’ new “virus finder system” helps keep operations running and employees safe
Hyris bKIT Virus Finder Covid-19 has been approved by Health Canada for point-of-care human testing
GUELPH, Ont. and LONDON — Since its approval by Health Canada for human testing in September, the Hyris Diagnostic Platform has been adopted by several Canadian companies as part of their COVID-19 risk-management planning, while many more are planning their rollouts with Songbird Life Science, Hyris’ strategic partner and exclusive distributor in Canada.
Deploying PCR (Polymerase Chain Reaction) technology, the Hyris Virus Finder system was created to keep people safe and operations running, according to the company.
“Our IoT diagnostic platform, driven by the power of artificial intelligence, is able to provide real-time data collection and interpretation, making the diagnostic results simple to ‘read’ even by ‘non-experts’ via its dedicated app,” Stefano lo Priore, founder and CEO of Hyris Ltd, a UK-based, biotechnology company, said in a prepared statement. “We are thrilled that more Canadians can now access COVID testing at point of care, when they need it, wherever they may be.”
As the “hardware heart” of the Hyris Virus Finder system, the “bCUBE” is a miniaturized portable device that has also been used for many years by Canadian genomic scientists at the University of Guelph, for the development of pharmaceutical and nutritional applications in an ongoing, well-established collaboration with Hyris Ltd. According to a company statement, the bCUBE confirms if the virus is onsite and allows for quick minimization of any negative impacts.
Songbird is currently coordinating with public agencies to deploy its testing device inventory to Canadians in remote communities and to those working in critical infrastructure and major manufacturers.